RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New CAR t therapy aims to control Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis early-stage study tests a new treatment called Equecabtagene Autoleucel (a CAR T-cell therapy) for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, which are modified in a …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing IASO Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Could a Once-Every-6-Week dose make a myeloma drug safer and more accessible?
Disease control Not yet recruitingThis study tests whether giving the drug belantamab mafodotin every 6 weeks (instead of every 3 weeks) is safe and effective for people with relapsed/refractory multiple myeloma who have tried at least 4 prior treatments. The goal is to see if this schedule can be used in communi…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Cristiana Costa Chase, DO • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New hope for myeloma patients Who've run out of options?
Disease control Not yet recruitingThis study tests a new drug called RO7851624 in about 160 people with multiple myeloma that has come back or stopped responding to standard treatments. The main goal is to check the drug's safety and how the body processes it. Participants must have tried several prior therapies …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New CAR-T therapy targets tough myeloma cases
Disease control Not yet recruitingThis early study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The main goal is to check safety…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
Engineered immune cells take aim at Hard-to-Treat myeloma
Disease control Not yet recruitingThis early-phase study tests a new treatment for people with a type of multiple myeloma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goals ar…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug SG2918 enters human trials
Disease control Not yet recruitingThis early-stage study tests a new drug called SG2918 in 40 people whose multiple myeloma has returned or not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. Researchers will also measure how the drug moves through th…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC